Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Burak Bilgin

Showing results (81-90 of 91) with videos related to

Pageof 10
Sort By:
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Scientific Reports|October 16, 2025
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group studySafa Can Efil, Burak Bilgin, Irem Bilgetekin, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Clinical Lung Cancer|August 14, 2025
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology GroupTuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
The Oncologist|September 7, 2023
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology GroupÇağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Pageof 10

Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Scientific Reports|October 16, 2025
Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group studySafa Can Efil, Burak Bilgin, Irem Bilgetekin, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Clinical Lung Cancer|August 14, 2025
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology GroupTuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
The Oncologist|September 7, 2023
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology GroupÇağlar Ünal, Abdulmunir Azizy, Senem Karabulut, et al.
Cancers|June 26, 2026
Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group StudyBahadır Köylü, Özde Melisa Celayir, Harun Muğlu, et al.
Clinical Breast Cancer|April 7, 2025
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) StudySeda Kahraman, Enes Erul, Ozge Gumusay, et al.
Pageof 10